Abstract: A surgical suture material with an antimicrobial surface is described, the surface exhibiting a coating containing a) at least one fatty acid, b) octenidine dichloride and/or dequalinium chloride and c) optionally oligomeric lactic acid esters. In addition, a process for coating surgical suture material is described which is characterized by the fact that the thread material is wetted with a homogeneous methanolic solution of octenidine dichloride and/or dequalinium chloride and subsequently the methanol is evaporated, a coating forming on the thread surface.

Abstract: Form bodies, which can be rotationally-symmetrical or irregularly-shaped, consist of at least one member of the group of the antibiotic salts, gentamicin myristate, gentamicin palmitate, gentamicin stearate, tobramycin myristate, tobramycin palmitate, tobramycin stearate, amikacin myristate, amikacin palmitate, amikacin stearate, vancomycin palmitate, vancomycin stearate, ramoplanin palmitate, ramoplanin stearate, levofloxacin palmitate, levofloxacin stearate, ofloxacin palmitate, ofloxacin stearate, moxifloxacin palmitate, moxifloxacin stearate, clindamycin palmitate, and clindamycin stearate. A medical device for implantation, in which the form bodies are arranged on a biodegradable filament at a distance of 1 mm to 25 mm as well as a method for the manufacture of the medical device and the use of the form bodies or the medical device to treat chronic osteomyelitis are described.

Abstract: A surgical suture material with an antimicrobial surface is described, the surface exhibiting a coating containing a) at least one fatty acid, b) octenidine dichloride and/or dequalinium chloride and c) optionally oligomeric lactic acid esters. In addition, a process for coating surgical suture material is described which is characterized by the fact that the thread material is wetted with a homogeneous methanolic solution of octenidine dichloride and/or dequalinium chloride and subsequently the methanol is evaporated, a coating forming on the thread surface.

Abstract: A polymethylmethacrylate bone cement with a liquid monomer component and a solid component contains in the monomer liquid, for example, 0.001-1.00 mass percent of a dye or dye mixture that is insoluble or poorly soluble in methacrylic acid methylester and, for example, 0.001-2.00 mass percent of a synthetically produced, protein-free, hydrophobic, low molecular or oligomeric solubilizer for the dye or dye mixture. The solubilizer preferably is liquid or pasty at room temperature. The monomer liquid is translucent at room temperature. Preferably, 0.001-1.00 mass percent of a dye or dye mixture that is insoluble or poorly soluble in methacrylic acid methylester and, preferably, 0.001-2.00 mass percent of a synthetically produced, protein-free, hydrophobic, low molecular or oligomeric solubilizer that is liquid or pasty at room temperature are homogeneously dissolved in the polymethacrylate or polymethylacrylate of the powder component.

Abstract: A local system for the liberation of an active principle is described which consists of spherical bodies which are composed of polymethyl methacrylate or polymethyl methacrylate co-methyl acrylate and, if necessary, zirconium dioxide and/or barium sulphate and a pharmaceutical active principle, which contains at least one hemostyptically effective compound stable at least up to 120° C., preferably a calcium salt. The local system for the liberation of an active principle is provided as medical product or drug.

Abstract: A dyed polymethyl methacrylate bone cement is described which is characterized by at least the surface of the polymer particles of the powder component being coated partially or completely with a mixture of one or several dyes and a hydrophobic, low molecular or oligomeric organic coupling agent, such a quantity of coupling agent being present that the polymer particles can be visually recognized as not having swollen.

Abstract: This describes a polymethylmethacrylate bone cement that is characterized in that it contains a hydrolytically-degradable X-ray opaquer with a Mohs hardness equal to or less than 3 and a water solubility at room temperature of less than 4 g per liter. The polymethylmethacrylate bone cement is used as temporary placeholder.

Abstract: The invention relates to a PMMA revision bone cement having powder and liquid component, in which the powder component contains two or more granular antibiotics whose grain size distribution is equal in that the main screening fraction each of the individual antibiotics is in the same grain size range, in particular in the range of 100-250 ?m or 150-250 ?m.

Abstract: A surgical suture material with an antimicrobial surface is described, the surface exhibiting a coating containing a) at least one fatty acid, b) octenidine dichloride and/or dequalinium chloride and c) optionally oligomeric lactic acid esters. In addition, a process for coating surgical suture material is described which is characterized by the fact that the thread material is wetted with a homogeneous methanolic solution of octenidine dichloride and/or dequalinium chloride and subsequently the methanol is evaporated, a coating forming on the thread surface.

Abstract: The invention relates to a method for the antibiotic coating of bodies with interconnecting microcavities as well as bodies coated this way and their usage.

Abstract: The invention relates to hardly soluble antiphlogistic salts and antiphlogistic-antibiotic pharmaceutical preparations and their use. The hardly water soluble antiphlogistic antibiotics salts have as their cationic component one of the antibiotics gentamicin, clindamycin, neomycin, streptomycin, tetracycline, doxicyline, oxytetracycline and rolitetracycline and as their anionic component one of the antiphlogistics ibuprofen, naproxen, indomethacin, dexamethasone-21-phosphate, dexamethasone-21-sulfate, triamcinolone-21-phosphate and triamcinolone-21-sulfate. The antiphlogistic antibiotics salts are used in pharmaceutical preparations as controlled-release antibiotic/antibiotics drugs.

Abstract: A bone replacement material that is, in particular, paste-like and is characterized in that particulate calcium carbonate is suspended in an aqueous solution that contains at least one water-soluble hemostatic agent, whereby the aqueous solution contains an amount of the hemostatic agent at which it is isotonic.

Abstract: A dental implant system component having a coating made of an only slightly water-soluble chlorhexidine fatty acid salt, in which one or more antiphiogistics and/or one or more steroids and/or one or more prostaglandins and/or one or more bisphosphonates and/or one or more statins are dissolved.

Abstract: One or more substances of the group consisting of gentamicin palmitate, gentamicin myristate, gentamicin laurate, tobramycin palmitate, tobramycin myristate, tobramycin laurate, amikacin palmitate, amikacin myristate, amikacin laurate, vancomycin palmitate, vancomycin laurate, and vancomycin myristate are suitable for providing vascular grafts with an antithrombogenically active principle.

Abstract: The invention describes pharmaceutical preparations with retarding active ingredient release, which consist of mixtures of powdery teicoplanin and at least one powdery, water soluble salt form of gentamicin, clindamycin, kanamycin, amikacin, tobramycin, vancomycin, moxifloxacin and ciprofloxacin and an inorganic and/or organic adjuvant. The pharmaceutical preparations are used as permanent or as temporary implants in the form of tablets, molded bodies, fibers and granules.

Abstract: Form bodies, which can be rotationally-symmetrical or irregularly-shaped, consist of at least one member of the group of the antibiotic salts, gentamicin myristate, gentamicin palmitate, gentamicin stearate, tobramycin myristate, tobramycin palmitate, tobramycin stearate, amikacin myristate, amikacin palmitate, amikacin stearate, vancomycin palmitate, vancomycin stearate, ramoplanin palmitate, ramoplanin stearate, levofloxacin palmitate, levofloxacin stearate, ofloxacin palmitate, ofloxacin stearate, moxifloxacin palmitate, moxifloxacin stearate, clindamycin palmitate, and clindamycin stearate. A medical device for implantation, in which the form bodies are arranged on a biodegradable filament at a distance of 1 mm to 25 mm as well as a method for the manufacture of the medical device and the use of the form bodies or the medical device to treat chronic osteomyelitis are described.

Abstract: A local system for the release of active principle is described which consists of approximately spherical or rotation symmetrical bodies which are composed essentially of polymethyl methacrylate or polymethyl methacrylate co-methyl acrylate, zirconium dioxide or barium sulphate and one or more pharmaceutical active principles, in particular antibiotics, and which are produced by radical polymerisation, radical polymerisation activators effective in the temperature range of 10-80° C. or residues of these polymerisation activators from the groups of aromatic amines, heavy metal salts and barbiturates not being contained therein.

Abstract: A method for producing antibiotic/antibiotics-particles characterized in that an aqueous solution of an amino glycoside-antibiotic or an aqueous solution comprising two or more amino glycoside-antibiotics is mixed under agitation with a solvent mixture comprising isopropanol and at least one additional alcohol, with the volume ratio of the solvent mixture to the aqueous solution being at least 3 to 1 and with the suspension developed being agitated until the primarily yielded coarse antibiotic/antibiotics aggregates disintegrate into particles, which have a grain size smaller than 400 ?m.

Abstract: A dyed polymethyl methacrylate bone cement is described which is characterised by at least the surface of the polymer particles of the powder component being coated partially or completely with a mixture of one or several dyes and a hydrophobic, low molecular or oligomeric organic coupling agent, such a quantity of coupling agent being present that the polymer particles can be visually recognised as not having swollen.

Abstract: A moldable implant material is described which is characterized in that a biodegradable or biocompatible monofilament or polyfilament thread is formed e.g. of polyester, polyamide, a corrodible iron alloy, magnesium, magnesium alloys, polysaccharides, polysaccharide derivatives, proteins, and/or protein derivatives or of combinations of these materials in such a way that, at a distance of 3-30 mm along the thread respectively, a circular loop and/or several circular loops are formed which have respectively a joint point of origin along the thread, at least 3 consecutive loops being present along the thread.